title: A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer.
abstract: BACKGROUND
  The objectives of this trial were to evaluate the activity and safety of gemcitabine carboplatin as induction therapy in patients with locally advanced non-small cell lung cancer
  
  
  METHODS
  Patients received two cycles of gemcitabine (1250 mg/m on day 1 and 8), plus carboplatin (area under the curve = 5 on day 1), after which response was established. Patients received a third course only in the case of an objective response (OR). Non-responding patients were directly irradiated. Toxicity was assessed according to the NCI-CTC version 2, radiation toxicity was assessed according to RTOG criteria. Response evaluation was performed according to RECIST criteria.
  
  
  RESULTS
  We identified 42 patients, of whom 37 were eligible. Of these, 51% (95% CI, 34%-68%) achieved an OR, all partial responses. No disease progression on therapy was established. Toxicity was mostly hematological: 35% trombocytopenia grade 3 and 4, and 40% neutropenia grade 3 and 4. No severe bleeding or hospitalization because of febrile neutropenia occurred.
  
  
  CONCLUSIONS
  Gemcitabine and carboplatin administered according to a 3-week schedule is an active and safe induction regimen. Pending the results of a phase III study, we believe that it is a reasonable alternative among patients for whom cisplatin-based chemotherapy is contraindicated.
authors.affiliation: Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands. j.aerts@sfg.nl
authors.forename: J G J V
authors.initials: JG
authors.lastname: Aerts
authors.forename: V
authors.initials: V
authors.lastname: Surmont
authors.forename: R J
authors.initials: RJ
authors.lastname: van Klaveren
authors.forename: K Y
authors.initials: KY
authors.lastname: Tan
authors.forename: S
authors.initials: S
authors.lastname: Senan
authors.forename: G
authors.initials: G
authors.lastname: van Wijhe
authors.forename: R
authors.initials: R
authors.lastname: Vernhout
authors.forename: G T
authors.initials: GT
authors.lastname: Verhoeven
authors.forename: H C
authors.initials: HC
authors.lastname: Hoogsteden
authors.forename: J P
authors.initials: JP
authors.lastname: van Meerbeeck
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016001:Confidence Intervals; D003718:Denmark; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine